Post-malaria neurological syndrome

被引:118
作者
Mai, NTH
Day, NPJ
VanChuong, L
Waller, D
Phu, NH
Bethell, DB
Hien, TT
White, NJ
机构
[1] CHO QUAN HOSP, CTR TROP DIS, WELLCOME TRUST CLIN RES UNIT, Ho Chi Minh City OX3 9DU, VIETNAM
[2] JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, CTR TROP MED, OXFORD, ENGLAND
基金
英国惠康基金;
关键词
D O I
10.1016/S0140-6736(96)01409-2
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background Neurological signs and symptoms are common in malaria, but observations in Vietnam and Thailand have pointed to a discrete transient neurological syndrome after recovery from severe infections. Methods A prospective study of the post-malaria neurological syndrome (PMNS) was conducted at two centres in Vietnam over four years. Criteria for inclusion were recent symptomatic malaria infection with parasites cleared from blood (and in cases of cerebral malaria full recovery of consciousness), and development of neurological or psychiatric symptoms within two months after the acute illness. Half of the patients with severe falciparum malaria had been taking part in a randomised trial of antimalarials. Findings Of 18 124 patients with falciparum malaria treated (1176 of whom had severe infections) 19 adults and three children had subsequent PMNS; in one patient it followed uncomplicated malaria and in 21 it followed severe malaria. The overall incidence (95% confidence interval) of PMNS after falciparum malaria at the main study centre was 1.2 per 1000 (0.7 to 18 per 1000) and relative risk (95% CI) for developing PMNS after severe versus uncomplicated falciparum malaria was 299 (40 to 2223). 13 patients had an acute confusional state or psychosis, six had one or more generalised convulsions, two had generalised convulsions followed by a long period of acute confusion, and one developed a fine tremor. At the time of PMNS diagnosis all patients were aparasitaemic. The syndrome was self-limiting, median duration 60 h (range 24-240). PMNS was associated with the use of oral mefloquine. In the randomised trial 44% (10/228) of patients with severe malaria who received mefloquine after parenteral treatment developed PMNS compared with 0.5% (1/210) of those who received quinine; relative risk 9.2 (95% CI 1.2 to 71.3, p=0.012). Interpretation Mefloquine is not the only risk factor for PMNS but it is a strong one. Where an effective alternative drug is available, mefloquine should not be used after treatment of severe malaria.
引用
收藏
页码:917 / 921
页数:5
相关论文
共 23 条
[1]
NEUROLOGICAL SEQUELAE OF CEREBRAL MALARIA IN CHILDREN [J].
BREWSTER, DR ;
KWIATKOWSKI, D ;
WHITE, NJ .
LANCET, 1990, 336 (8722) :1039-1043
[2]
FATAL OUTCOME IN JAPANESE ENCEPHALITIS [J].
BURKE, DS ;
LORSOMRUDEE, W ;
LEAKE, CJ ;
HOKE, CH ;
NISALAK, A ;
CHONGSWASDI, V ;
LAORAKPONGSE, T .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1985, 34 (06) :1203-1210
[3]
IMMUNE ACTIVATION DURING CEREBELLAR DYSFUNCTION FOLLOWING PLASMODIUM-FALCIPARUM MALARIA [J].
DESILVA, HJ ;
HOANG, P ;
DALTON, H ;
DESILVA, NR ;
JEWELL, DP ;
PEIRIS, JB .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1992, 86 (02) :129-131
[4]
A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria [J].
Hien, TT ;
Day, NPJ ;
Phu, NH ;
Mai, NTH ;
Chau, TTH ;
Loc, PP ;
Sinh, DX ;
Chuong, LV ;
Vinh, H ;
Waller, D ;
Peto, TEA ;
White, NJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :76-83
[5]
Hosmer D., 1989, APPL LOGISTIC REGRES
[6]
MEFLOQUINE FOR MULTIDRUG-RESISTANT MALARIA [J].
LUXEMBURGER, C ;
NOSTEN, F ;
TERKUIILE, F ;
FREJACQUES, L ;
CHONGSUPHAJAISIDDHI, T ;
WHITE, NJ .
LANCET, 1991, 338 (8777) :1268-1268
[7]
MACPHERSON GG, 1985, AM J PATHOL, V119, P385
[8]
ESTIMATION OF RELATIVE RISK FROM INDIVIDUALLY MATCHED SERIES [J].
MIETTINEN, OS .
BIOMETRICS, 1970, 26 (01) :75-+
[9]
MOOD AM, 1963, INTRO THEORY STATIST
[10]
ADULT MORTALITY IN DEVELOPING-COUNTRIES [J].
MURRAY, CJL ;
FEACHEM, RGA .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1990, 84 (01) :1-2